Welcome to vnonline.co.uk

vnonline.co.uk provides the veterinary nursing profession with the latest news and industry developments, as well as events, resources, learning materials and careers.

Our website is dedicated to veterinary nurses and we strive to provide a platform where you can voice and explore your interests.

Not a member yet? Sign up for free!

Register for free with vnonline.co.uk to gain unlimited access to news, resources, jobs and much more!



Click here to become a member






Log in to vnonline

Forgot your password?

Posted: 31st October 2016

RHDV-2 vaccine authorised in the EU
rabbits
The VMD says vets should use their clinical judgement on a case by case basis to decide the most suitable vaccination protocol.
Marketing authorisation issued for ERAVAC

The European Medicines Agency (EMA) has issued a marketing authorisation for the vaccine ERAVAC, to reduce mortality caused by rabbit haemorrhagic disease virus type 2 (RHDV-2).

Recent analysis by the Animal and Plant Health Agency (APHA) revealed RHDV-2 has been present in Great Britain since 2010 and was found across England, Scotland and Wales. The findings prompted some concern due to the lack of a vaccine.

ERAVAC is produced by Laboratorios Hipra, S.A. and is indicated for the active immunisation of fattening rabbits from the age of 30 days. The marketing authorisation is valid throughout the European Union.

The Veterinary Medicines Directorate (VMD) says it will accept applications to import unauthorised medicines into the UK to treat RHDV-2, if ERAVAC is not available or suitable.

Vaccines against RHDV-2 - such as Filavac VHD K C+V (France) and Novarvipal (Spain) - are authorised in other EU countries. These have previously been imported by UK veterinary surgeons under the Special Import Scheme.

There is no available information on the safety and efficacy of RHDV-2 vaccines for pet rabbits, including when they are used alongside other vaccines (such as classical RHDV or myxomatosis vaccines).

The VMD says vets should use their clinical judgement on a case by case basis to decide the most suitable vaccination protocol. Vets are advised to contact the vaccine manufacturer directly for further information.



Become a member or log in to add this story to your CPD history



Latest news | Careers | Events | Resources | Contact us | Terms and conditions | Data Protection and Privacy |Cookie policy | About us | Copyright
© 2024 Vision Media, all rights reserved. vnonline.co.uk is not responsible for the content of external websites.